Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2011

View Archived Issues

New model developed to evaluate pharmacodynamics of antimicrobial agents and design dosing regimens

Phase III data presented on long-term safety and tolerability of degarelix in prostate cancer

Novartis profiles achievements of 2010

Lucentis improves vision in patients with diabetic macular edema in phase III RISE trial

Oxigene and NCI collaborate on phase II Zybrestat trial in ovarian cancer

Enrollment begins in Diamyd's phase II NP2 enkephalin trial in cancer pain

Ginseng metabolite S-111 has potent antidepressant effects in vivo

SMB recommends continuation of Vical's phase III Allovectin-7 trial in metastatic melanoma

Abbott identifies novel inhibitors of Cdc7

Gold nanoshells with silica nanorattle cores combine photo- and chemotherapy to treat cancer

Axcan Pharma acquires Eurand

DMC recommends continuation of phase III ThermoDox HEAT trial

Bayer Schering claims new [18F]-labeled PET imaging agents

Novel autotaxin inhibitors claimed

Beta Pharma patents new activators of hypoxia-inducible factor 1

Kamada receives interim report of phase II/III trial of inhaled alpha-1 antitrypsin

NurOwn autologous adult stem cell product receives FDA orphan drug status in ALS

PROLOR's phase II trial of long-acting human growth hormone proceeds as planned

Polaris and LICR begin phase II trial of ADI-PEG 20 in SCLC

Tarsa completes phase III trial of oral calcitonin in osteoporosis

Marina Biotech provides update on development of oligonucleotide-based therapeutics

Endpoint met in first part of phase II trial of Reolysin and gemcitabine in pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...